CellSeed Inc. (7776.T)
JPY 408.0
(-7.69%)
JPY 408.0
(-7.69%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -836.51 Million JPY | 5.95% |
| 2022 | -750 Million JPY | 13.55% |
| 2021 | -905.67 Million JPY | -17.37% |
| 2020 | -770.13 Million JPY | 10.45% |
| 2019 | -776.89 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -231.57 Million JPY | -6.31% |
| 2024 Q1 | -230.96 Million JPY | 11.7% |
| 2023 Q2 | -182.12 Million JPY | 1.11% |
| 2023 Q4 | -122.73 Million JPY | 44.25% |
| 2023 FY | - JPY | 5.95% |
| 2023 Q1 | -184.16 Million JPY | -4.23% |
| 2023 Q3 | -220.12 Million JPY | -20.87% |
| 2022 Q3 | -213.71 Million JPY | 0.0% |
| 2022 FY | - JPY | 13.55% |
| 2022 Q4 | -176.69 Million JPY | 17.32% |
| 2021 FY | - JPY | -17.37% |
| 2020 FY | - JPY | 10.45% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 187.31% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -71.371% |
| GNI Group Ltd. | 14.48 Billion JPY | 105.774% |
| Linical Co., Ltd. | 1.24 Billion JPY | 167.07% |
| Trans Genic Inc. | 240.95 Million JPY | 447.171% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 38.303% |
| Soiken Holdings Inc. | -583.2 Million JPY | -43.434% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -38.705% |
| AnGes, Inc. | -8.86 Billion JPY | 90.559% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 34.926% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 88.694% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 752.982% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 3.069% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 23.381% |
| CanBas Co., Ltd. | 53.65 Million JPY | 1659.181% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | -7.855% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -648.219% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 30.966% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 39.419% |
| PeptiDream Inc. | 7.37 Billion JPY | 111.341% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 56.65% |
| Ribomic Inc. | -1.01 Billion JPY | 17.383% |
| SanBio Company Limited | -4.52 Billion JPY | 81.513% |
| Healios K.K. | -3 Billion JPY | 72.181% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 28.244% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 39.952% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 40.334% |
| StemRIM | -2.03 Billion JPY | 58.833% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 164.03% |
| FunPep Company Limited | -952 Million JPY | 12.131% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 5.879% |
| Stella Pharma Corporation | -723.85 Million JPY | -15.564% |
| TMS Co., Ltd. | -937 Million JPY | 10.724% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -7.883% |
| Cuorips Inc. | -518 Million JPY | -61.49% |
| K Pharma,Inc. | 366.05 Million JPY | 328.52% |
| Takara Bio Inc. | 8.02 Billion JPY | 110.425% |
| ReproCELL Incorporated | 8.24 Million JPY | 10245.737% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 1051.257% |
| StemCell Institute Inc. | 534.35 Million JPY | 256.547% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 441.695% |